For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.
Patients with indeterminate chronic hepatitis B (CHB) phase are at risk of progressing to advanced liver disease and hepatocellular carcinoma (HCC), according to study results published in the Journal ...